Literature DB >> 11524478

Fatigue is not associated with raised inflammatory markers in multiple sclerosis.

G Giovannoni1, A J Thompson, D H Miller, E J Thompson.   

Abstract

BACKGROUND: The pathogenesis of fatigue in patients with MS is poorly understood.
OBJECTIVE: To test the hypothesis that fatigue in MS is related to inflammatory disease activity as measured by systemic markers of inflammation.
METHODS: Fatigue as assessed by the Fatigue Questionnaire Scale (FQS) and Krupp's Fatigue Severity Scale (KFSS) was correlated with several inflammatory markers in 38 patients with MS (16 relapsing-remitting [RR; 7 of whom had benign MS), 9 secondary progressive [SP], 13 primary progressive [PP]). The markers included daily urinary neopterin excretion, a marker of interferon-gamma-activated macrophage activity, and serum C-reactive protein (CRP) and soluble intercellular adhesion molecule-1 (sICAM-1) levels. Urinary neopterin excretion was measured daily for 2 weeks.
RESULTS: No correlation was found between urinary neopterin excretion, CRP, or sICAM-1 and the fatigue scores. However, patients with a raised serum CRP level had higher KFSS, but not FQS, scores than patients with normal CRP levels (KFSS, 50 +/- 8 vs 41 +/- 14, p = 0.05; FQS, 13 +/- 4 vs 11 +/- 5, p = NS). When assessed using the FQS, patients with RR and SP MS were more fatigued than patients with PP MS (RR = 12.5 [4 to 23] vs SP = 13 [8 to 18] vs PP = 9 [7 to 14], p = 0.02). The patients with benign MS were as fatigued as patients with nonbenign disease.
CONCLUSION: The pathogenesis of fatigue in MS is complex and does not appear to be directly related to systemic markers of inflammatory disease activity. Interestingly, patients with PP MS were less fatigued than patients with RR disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524478     DOI: 10.1212/wnl.57.4.676

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

Review 1.  Fatigue in multiple sclerosis: definition, pathophysiology and treatment.

Authors:  Lauren B Krupp
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Multiple sclerosis related fatigue.

Authors:  G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

3.  Biological outcome measurements for behavioral interventions in multiple sclerosis.

Authors:  Anja Fischer; Christoph Heesen; Stefan M Gold
Journal:  Ther Adv Neurol Disord       Date:  2011-07       Impact factor: 6.570

4.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

5.  Fatigue and progression of corpus callosum atrophy in multiple sclerosis.

Authors:  Özgür Yaldizli; Stephanie Glassl; Dietrich Sturm; Athina Papadopoulou; Achim Gass; Barbara Tettenborn; Norman Putzki
Journal:  J Neurol       Date:  2011-05-19       Impact factor: 4.849

6.  The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis--a pilot study.

Authors:  Roald Omdal; Ragnar Gunnarsson
Journal:  Rheumatol Int       Date:  2004-04-08       Impact factor: 2.631

7.  Association of C-reactive protein and interleukin-6 with new-onset fatigue in the Whitehall II prospective cohort study.

Authors:  H J Cho; M Kivimäki; J E Bower; M R Irwin
Journal:  Psychol Med       Date:  2012-11-14       Impact factor: 7.723

Review 8.  Depression and immunity: inflammation and depressive symptoms in multiple sclerosis.

Authors:  Stefan M Gold; Michael R Irwin
Journal:  Immunol Allergy Clin North Am       Date:  2009-05       Impact factor: 3.479

9.  Prospective association between C-reactive protein and fatigue in the coronary artery risk development in young adults study.

Authors:  Hyong Jin Cho; Teresa E Seeman; Julienne E Bower; Catarina I Kiefe; Michael R Irwin
Journal:  Biol Psychiatry       Date:  2009-07-29       Impact factor: 13.382

10.  Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort.

Authors:  John P Zajicek; Wendy M Ingram; Jane Vickery; Siobhan Creanor; Dave E Wright; Jeremy C Hobart
Journal:  BMC Neurol       Date:  2010-10-07       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.